Navigation Links
PCAS : Tighter Links Between PCAS and Proteus
Date:10/22/2007

LONGJUMEAU, France, October 22 /PRNewswire-FirstCall/ -- Proteus today announced the completion of a share capital increase reserved for Proteus' industrial partner PCAS. PCAS' stake in Proteus now represents 32% of the issued share capital vs 6% before the increase. Proceeds of this private placement are to be used to accelerate the growth of PROTEUS' PSI and PCAS BIOSOLUTION businesses.

PROTEUS (http://www.proteus.fr) is a biotech company discovering, optimizing, developing and producing new proteins and biotechnological processes for pharmaceuticals, cosmetics, fine chemicals, environmental and other industrial applications. PROTEUS' business is backed by a unique set of technologies, know how and intellectual property portfolio including exclusive resources in natural microbial biodiversity and proprietary technologies for screening, engineering and producing proteins.

PROTEUS offers a range of exclusive solutions for protein manufacturing and engineering through a dedicated business unit "PSI" (Proteus Services for Industry) and through exclusive industrial partnerships. The new proteins and process developed by PROTEUS reinforce the competitive edge and intellectual property position of its clients.

PCAS and PROTEUS already entered into close partnership by forming PCAS BIOSOLUTION, a 50/50 joint venture. The mission of PCAS BIOSOLUTION (http://www.pcas-bio.com) is to design, develop and industrialize new manufacturing routes to produce pharmaceutical intermediates and actives compounds ("API"). The new routes combines chemical processes developed by PCAS and enzymatic catalytic processes ("biocatalysis") developed by PROTEUS.

PCAS thus reinforces its position in "green chemistry", providing its clients with all the benefits of integrating chemistry and biotechnology. The new chemo-biocatalytic processes developed at PCAS BIOSOLUTION enable to access to complex pharmaceutical intermediates while reducing the number of steps of the manufacturing process, lowering the production costs and reducing the amount of waste. With PCAS BIOSOLUTION, PROTEUS improves and widens its offering to the life science industry by providing industrial manufacturing services backed by the expertise and industrial capabilities of PCAS, a leading European player in the field.

PCAS (http://www.pcas.fr) is a group listed on the Eurolist compartment C (ISIN FR0000053514), specialized in fine and specialty chemicals. It develops and manufactures high added-value molecules or molecules of a strong technological content for the pharmaceutical, perfume, cosmetic and industrial sectors.

Contact :

Gérard Guillamot,

+33(0)1-69-79-60-08

http://www.pcas.fr


'/>"/>
SOURCE PCAS
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Investor links East Coast funds to Midwest tech
2. UW links with Israeli school to locate genes
3. New Dane County airport links to Atlanta announced
4. Big collaboration links learners to science on a tiny scale
5. ARI Links e-Catalog Deal with Outdoor Power Equipment Manufacturer
6. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
7. Quantitative Measurement of Cell Proliferation Using the BrdU ELISA: A Comparison Between Colorimetric and Chemiluminescent Detection
8. Monitoring fluorescence resonance energy transfer (FRET) between GFP fusions in lysates of the yeast Saccharomyces cerevisiae using the Varian Cary Eclipse
9. Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP
10. Single gene controls key difference between maize and its wild ancestor
11. Line between big pharma, big biotech continues to blur
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
Breaking Biology Technology:
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):